Nuformix PLC Directorate Changes (4996Z)
24 May 2021 - 4:00PM
UK Regulatory
TIDMNFX
RNS Number : 4996Z
Nuformix PLC
24 May 2021
Nuformix plc
("Nuformix" or the "Company")
Directorate Changes
Appointment of Chairman and other Board changes
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces the appointment of Dr Alastair Riddell as
Non-Executive Chairman of the Board with immediate effect. In
addition, the Company announces the resignations of Dr Karl Keegan
as Non-Executive Director and Dr Joanne Holland as Chief Scientific
Officer.
Dr Alastair Riddell will join Nuformix as Non-Executive Chairman
of the Board with immediate effect. Alastair brings a wealth of
leadership experience in public and private biotech companies to
Nuformix, gained over 30 years in the pharmaceutical, life science
and biotech industries, with 20 years as a Board Director. After
beginning his career as a medical doctor in hospital and general
practice, he moved into clinical development for Lederle (now
Pfizer) and Centocor (now J&J) and then sales and marketing for
Amersham International (now GE Healthcare). This led to 12 years as
CEO for three UK biotech companies, Pharmagene, Paradigm
Therapeutics and Stem Cell Sciences, where he led significant
fundraises including an IPO on the LSE main list and trade sales to
Takeda in Japan and Stem Cells Inc. in the USA. He has also had
several roles in UK government initiatives including assessing
projects for Innovate UK funding. He then moved to Non-Executive
roles including for NASDAQ-listed AzurRx (AZRX), Cristal
Therapeutics and was Chairman of AIM quoted Feedback plc and
Nemesis Biosciences. Alastair has a BSc from Aston University, a
MSc and MBChB from the University of Birmingham and an Honorary
Degree of Doctor of Science from Aston University.
Dr Karl Keegan has resigned from the Board, with immediate
effect in order to focus on his other executive role that he has
recently taken on. Dr Joanne Holland has resigned as a director and
an employee of Nuformix from the end of May 2021 in order to pursue
other opportunities. However, she will continue as a consultant to
Nuformix to advise, in particular, on solid form science and
patenting.
Dr Anne Brindley, CEO of Nuformix said: "I would like to welcome
Alastair to the Board of Nuformix and look forward to working with
him. Alastair will bring extensive experience of pharma and biotech
which will be invaluable as we take Nuformix forward as a Company.
I would like to sincerely thank Karl for his valuable and
insightful contributions to Nuformix over the last year or so and
we wish him all the best for the future.
"On behalf of the Board, I would also like to thank Jo for her
long-standing commitment and contributions to Nuformix. She has
been with the Company from its inception providing expert knowledge
and input into the design and patenting of novel physical forms of
existing drugs that has resulted in the product concepts we have
today in the Nuformix portfolio. We are very pleased that Jo will
continue to provide support as needed in these areas as the
Nuformix portfolio moves forward in development. We sincerely wish
Jo all the best in the future and look forward to our continued
working together in a renewed capacity."
Dr. Alastair Riddell said: "I am delighted to be able to join
Nuformix as it develops its portfolio of newly formulated
established products for new and important therapeutic indications.
I look forward to helping the company progress these opportunities
to value creation for shareholders in the next few years."
Enquiries:
Nuformix plc +44 (0)1223 627222
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0)203 328 5656
Nick Athanas / George Payne (Corporate
Finance)
Tim Sohal / Matt Butlin (Sales and
Corporate Broking)
Walbrook PR
Anna Dunphy / Paul McManus / Kiki
Zaccagnini +44 (0)207 933 8780
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUAUNRAUUVUAR
(END) Dow Jones Newswires
May 24, 2021 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024